메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
박상현 (성균관대학교 의과대학 강북삼성병원 소화기내과)
저널정보
대한내분비학회 Endocrinology and Metabolism Endocrinology and Metabolism Vol.34 No.1
발행연도
2019.1
수록면
70 - 79 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: We aimed to retrospectively analyze the efficacy of 10 mg dapagliflozin (DAPA), which is a sodium-glucose cotransporter-2 inhibitor, in Korean patients with type 2 diabetes who visited a primary diabetes clinic. Methods: In total, 83 patients with type 2 diabetes, who received treatment with DAPA for the first time in a primary diabetes clinicbetween January 2015 and October 2015, were included in the study. The effect of DAPA in lowering glycosylated hemoglobin(HbA1c) levels was evaluated via chart review at 6 months follow-up. The patients were categorized into five groups according toadd-on to or switched from other glucose-lowering agents: add-on to metformin (MET, n=10), add-on to MET+dipeptidyl peptidase4 inhibitor (DPP4i, n=12), switched from sulfonylurea (SU, n=13), switched from DPP4i (n=11), and switched from thiazolidinedione (TZD, n=37). All the participants had already used MET for their regimen. Results: Treatment with DAPA reduced HbA1c level by 1.2%±0.8%. Moreover, a significant decrease was observed in all subgroups: add-on to MET, –1.2%±0.7%; add-on to MET+DPP4i, –1.4%±0.8%; switched from SU, –1.4%±0.7%; switched fromDPP4i, –0.5%±0.7%; and switched from TZD, –1.2%±0.9% (P<0.01). A significant decrease in body weight (–3.1±2.6 kg,P<0.001) was observed after DAPA administration. Estimated glomerular filtration rate and urine microalbumin were significantlydecreased after 6 months of treatment with DAPA (–4.0±13.5 mL/min/1.73 m2, P=0.03; –23.6±45.9 mg/L, P<0.001). Conclusion: Treatment with DAPA, whether added to or switched from other glucose-lowering agents, significantly decreasedHbA1c levels in Korean patients with type 2 diabetes who visited a single primary diabetes clinic. DAPA can be considered as anoptimal second-line treatment for patients with type 2 diabetes, as supported by real-world evidence studies.

목차

등록된 정보가 없습니다.

참고문헌 (36)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0